CA3045644C - Antagonistes du recepteur glp-1 et leurs utilisations - Google Patents

Antagonistes du recepteur glp-1 et leurs utilisations Download PDF

Info

Publication number
CA3045644C
CA3045644C CA3045644A CA3045644A CA3045644C CA 3045644 C CA3045644 C CA 3045644C CA 3045644 A CA3045644 A CA 3045644A CA 3045644 A CA3045644 A CA 3045644A CA 3045644 C CA3045644 C CA 3045644C
Authority
CA
Canada
Prior art keywords
methyl
compound
benzimidazole
benzodioxol
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3045644A
Other languages
English (en)
Other versions
CA3045644A1 (fr
Inventor
Gary Erik Aspnes
Scott W. Bagley
John M. Curto
David James EDMONDS
Mark E. Flanagan
Kentaro Futatsugi
David A. Griffith
Kim HUARD
Yajing Lian
Chris Limberakis
Allyn T. Londregan
Alan M. Mathiowetz
David W. Piotrowski
Roger B. Riggeri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3045644A1 publication Critical patent/CA3045644A1/fr
Application granted granted Critical
Publication of CA3045644C publication Critical patent/CA3045644C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)

Abstract

Il est décrit des composés de la formule I (consultez la formule I), et des sels connexes acceptables sur le plan pharmaceutique, comme agonistes du récepteur de peptide 1 de type Glucagon qui peuvent être utiles pour traiter la stéatohépatite non alcoolique, le diabète ou lobésité; des procédés pour fabriquer lesdits composés; et des méthodes dutilisation desdits composés chez un mammifère en ayant besoin.
CA3045644A 2018-06-13 2019-06-10 Antagonistes du recepteur glp-1 et leurs utilisations Active CA3045644C (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862684696P 2018-06-13 2018-06-13
US62/684696 2018-06-13
US201962846944P 2019-05-13 2019-05-13
US62/846944 2019-05-13
US201962851206P 2019-05-22 2019-05-22
US62/851206 2019-05-22

Publications (2)

Publication Number Publication Date
CA3045644A1 CA3045644A1 (fr) 2019-12-13
CA3045644C true CA3045644C (fr) 2024-01-16

Family

ID=67003576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045644A Active CA3045644C (fr) 2018-06-13 2019-06-10 Antagonistes du recepteur glp-1 et leurs utilisations

Country Status (41)

Country Link
US (6) US10934279B2 (fr)
EP (2) EP3806955B9 (fr)
JP (1) JP6916968B1 (fr)
KR (1) KR102542199B1 (fr)
CN (4) CN119431342A (fr)
AU (1) AU2019285491B2 (fr)
BR (1) BR112020024470A2 (fr)
CA (1) CA3045644C (fr)
CL (1) CL2020003222A1 (fr)
CO (1) CO2020015305A2 (fr)
CR (1) CR20200612A (fr)
CU (1) CU20200099A7 (fr)
CY (1) CY1126097T1 (fr)
DK (2) DK4219487T5 (fr)
EC (1) ECSP20078651A (fr)
ES (2) ES3012643T3 (fr)
FI (2) FI4219487T3 (fr)
GE (2) GEP20227453B (fr)
HR (2) HRP20230631T1 (fr)
HU (2) HUE063074T2 (fr)
IL (1) IL279300B2 (fr)
LT (2) LT3806955T (fr)
MA (1) MA64510B1 (fr)
MD (2) MD4219487T3 (fr)
MX (1) MX389121B (fr)
MY (1) MY199157A (fr)
NI (1) NI202000091A (fr)
NZ (1) NZ770240A (fr)
PE (2) PE20240584A1 (fr)
PH (1) PH12020552069A1 (fr)
PL (2) PL4219487T3 (fr)
PT (2) PT4219487T (fr)
PY (1) PY1946939A (fr)
RS (2) RS64323B9 (fr)
SG (1) SG11202011465QA (fr)
SI (2) SI3806955T1 (fr)
TW (1) TWI707683B (fr)
UA (1) UA124371C2 (fr)
UY (1) UY38261A (fr)
WO (1) WO2019239319A1 (fr)
ZA (1) ZA202007572B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045644C (fr) 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
ES2943510T3 (es) 2018-06-15 2023-06-13 Pfizer Agonistas del receptor GLP-1 y usos del mismo
CR20210341A (es) * 2018-11-22 2021-11-25 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2020234726A1 (fr) * 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CA3157525A1 (fr) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Composes modulateurs de glp-1r
MX2022007105A (es) * 2019-12-10 2022-07-11 Pfizer Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
FI4073051T3 (fi) 2019-12-10 2024-03-28 Lilly Co Eli Menetelmä ja välituote oksetan-2-yylimetanamiinin valmistamiseksi
WO2021154796A1 (fr) * 2020-01-29 2021-08-05 Gilead Sciences, Inc. Composés modulateurs de glp-1r
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
FI4143183T3 (fi) * 2020-04-29 2026-01-07 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
US20230234968A1 (en) * 2020-06-10 2023-07-27 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
WO2021254470A1 (fr) * 2020-06-19 2021-12-23 江苏恒瑞医药股份有限公司 Dérivé de 6-oxo-3,6-dihydropyridine, son procédé de préparation et son utilisation en médecine
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
TW202214622A (zh) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
WO2022042691A1 (fr) * 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
AU2021306414B2 (en) * 2020-09-01 2026-01-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4211139A4 (fr) 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2022068772A1 (fr) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
EP4229050A4 (fr) * 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
EP4247804A1 (fr) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Composés modulateurs de glp-1r polyhétérocycliques
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US20220193063A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
US12065434B2 (en) 2020-12-15 2024-08-20 Pfizer Inc. Metabolites of GLP1R agonists
CA3209593A1 (fr) * 2021-01-28 2022-08-04 Carmot Therapeutics, Inc. Agonistes du recepteur gpcr, compositions pharmaceutiques les comprenant, et leurs procedes d'utilisation
WO2022184849A1 (fr) 2021-03-04 2022-09-09 Les Laboratoires Servier Agonistes de glp-1r, utilisations et compositions pharmaceutiques associées
EP4304711A1 (fr) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Composés modulateurs de glp-1r
WO2022192430A1 (fr) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Composés modulateurs de glp-1r
WO2022202864A1 (fr) 2021-03-24 2022-09-29 塩野義製薬株式会社 Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
KR20230170034A (ko) * 2021-04-12 2023-12-18 노파르티스 아게 비만 치료를 위한 glp1 수용체의 활성화제로서의 2-((4-((s)-2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((s)-옥세탄-2-일)메틸)-1h-이미다졸 유도체
WO2022219495A1 (fr) 2021-04-12 2022-10-20 Novartis Ag Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité
CN117222644A (zh) * 2021-04-12 2023-12-12 诺华股份有限公司 2-((4-((S)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-咪唑衍生物作为GLP1受体激活剂治疗肥胖症
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
WO2022228490A1 (fr) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 Modulateur de dérivé polycyclique, son procédé de préparation et son utilisation
WO2022235717A1 (fr) * 2021-05-03 2022-11-10 Carmot Therapeutics, Inc. Agonistes du récepteur benzimidazoyl glp-1, compositions pharmaceutiques les comprenant, et leurs procédés d'utilisation
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023001237A1 (fr) * 2021-07-21 2023-01-26 Hepagene Therapeutics (HK) Limited Modulateurs du récepteur du peptide-1 similaire au glucagon et leurs utilisations
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
EP4382525A4 (fr) * 2021-08-04 2025-07-16 Shanghai Hansoh Biomedical Co Ltd Régulateur de dérivé de cycloalcène, son procédé de préparation et son utilisation
WO2023025201A1 (fr) * 2021-08-24 2023-03-02 南京明德新药研发有限公司 Composé imidazocyclique et son application
IL310377A (en) 2021-08-30 2024-03-01 Mindrank Ai Ltd Novel aryl ether substituted heterocyclic compound as glp1r agonist
WO2023038039A1 (fr) 2021-09-08 2023-03-16 塩野義製薬株式会社 Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité
KR20240068737A (ko) * 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
WO2023057414A1 (fr) * 2021-10-05 2023-04-13 Astrazeneca Ab Certaines octahydrofuro 3,4-b]pyrazines utilisées en tant que modulateurs du récepteur glp-1
AU2022358915A1 (en) * 2021-10-05 2024-05-09 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (fr) 2021-10-05 2023-04-13 Astrazeneca Ab Certains 2,5-diazabicyclo[4.2.0]octanes et octahydrofuro[3,4-b]pyrazines utilisés en tant que modulateurs du récepteur glp-1
CN115991685B (zh) * 2021-10-20 2025-03-04 韶远科技（上海)有限公司 一种氧杂环丁烷-2-甲胺的制备方法
TWI843243B (zh) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JPWO2023106310A1 (fr) * 2021-12-07 2023-06-15
CN113974618B (zh) * 2021-12-12 2022-09-13 广西澍源智能科技有限公司 基于水峰血糖修正的无创血糖测试方法
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (fr) 2021-12-16 2023-06-22 Astrazeneca Ab Certains 3-azabicyclo[3.1.0] hexanes utilisés en tant que modulateurs du récepteur de glp-1
US20250049777A1 (en) * 2021-12-23 2025-02-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
EP4725484A2 (fr) * 2021-12-23 2026-04-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Forme cristalline d'un agoniste du récepteur glp-1 et son procédé de préparation
CN116354945B (zh) * 2021-12-27 2024-08-30 长春金赛药业有限责任公司 一种稠合咪唑羧酸类化合物及其制备方法和应用
CN119343343A (zh) * 2022-02-09 2025-01-21 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023151575A1 (fr) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Agonistes hétérocycliques de glp-1
EP4476212A1 (fr) 2022-02-10 2024-12-18 Novartis AG Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CA3253533A1 (fr) * 2022-02-28 2023-08-31 Ascletis Bioscience Co., Ltd. Composés modulateurs de glp-1r
WO2023169436A1 (fr) * 2022-03-08 2023-09-14 广州市联瑞制药有限公司 Composé benzo bicyclique, son procédé de préparation et son application
WO2023228023A1 (fr) * 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
IL319453A (en) * 2022-09-06 2025-05-01 Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd Polymorph of a GLP-1R agonist compound, method of preparation thereof and use thereof
US20260097037A1 (en) 2022-09-22 2026-04-09 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
WO2024102625A1 (fr) 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon
IL320810A (en) 2022-11-16 2025-07-01 Lilly Co Eli Glucagon-like peptide 1 receptor agonists
CN115785066B (zh) 2022-12-08 2024-05-31 广东工业大学 曲格列汀晶型f及其制备方法
JP2026500865A (ja) 2023-01-13 2026-01-08 中国科学院上海薬物研究所 Ｇｌｐ－１受容体アゴニストとして使用される４－アルコキシベンゾイミダゾール－６－カルボン酸誘導体
EP4660194A1 (fr) * 2023-02-02 2025-12-10 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Sel et forme cristalline de composé cycloalcène, leur procédé de préparation et leur utilisation
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
EP4695226A1 (fr) 2023-04-14 2026-02-18 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
CN118812522A (zh) * 2023-04-21 2024-10-22 苏州闻泰医药科技有限公司 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用
WO2025015269A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Composés, compositions et procédés
WO2025015268A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulateurs de l'activité du récepteur de la calcitonine et/ou du récepteur de l'amyline
USD1011080S1 (en) 2023-07-28 2024-01-16 Voilasophy, Llc. Yoga storage rack
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025104668A1 (fr) 2023-11-17 2025-05-22 Pfizer Inc. Anticorps anti-récepteur polypeptidique inhibiteur gastrique (gipr) et conjugués d'anticorps pour traiter des troubles métaboliques
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
TW202543613A (zh) * 2023-12-27 2025-11-16 香港商英矽智能科技知識產權有限公司 作為ｇｌｐ－１ｒ激動劑的新型化合物及其用途
TW202542163A (zh) * 2023-12-27 2025-11-01 香港商英矽智能科技知識產權有限公司 作為ｇｌｐ－１ｒ激動劑的新型化合物及其用途
WO2025158275A1 (fr) * 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025171340A1 (fr) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Traitement d'états associés au récepteur de la calcitonine et/ou de l'amyline
WO2025171341A2 (fr) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Composés et compositions pour traiter des états associés au récepteur de la calcitonine et/ou à l'activité du récepteur de l'amyline
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224648A1 (fr) 2024-04-26 2025-10-30 Pfizer Inc. Compositions/formulations orales de l'acide 2-({4-[(2s)-2-(4-chloro-2-fluorophényl)-2-méthyl-1,3-benzodioxol-4-yl]pipéridin-1-yl}méthyl)-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci
WO2026013531A1 (fr) 2024-07-10 2026-01-15 Pfizer Inc. Composés spiro[2,5]octane
WO2026033382A1 (fr) 2024-08-07 2026-02-12 Pfizer Inc. Modulateurs hétérocycliques de glp-1 r
WO2026042018A1 (fr) 2024-08-21 2026-02-26 Pfizer Inc. Dérivés d'acide 4-4-[(1-{[4-(propan-2-yl) phényl] carbamoyl)-d-prolyl)amino]cyclohexyl}benzoïque en tant qu'antagonistes de gipr pour le traitement du diabète
WO2026051998A1 (fr) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Composés, compositions et procédés
WO2026078617A1 (fr) 2024-10-11 2026-04-16 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
WO2026078670A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Dérivés hétérocycliques en tant qu'antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose
WO2026078671A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Composés hétérocycliques utilisés en tant qu'antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose
WO2026078673A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose et leurs utilisations
WO2026078672A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
WO2026078674A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Dérivés hétérocycliques utilisés en tant qu'antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose et leurs utilisations

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2156836A1 (fr) 1993-03-18 1994-09-29 Janusz Jozef Kulagowski Derives du benzimidazole
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
EP1235572A2 (fr) 1999-10-29 2002-09-04 MERCK SHARP & DOHME LTD. Procede de traitement de la douleur a l'aide d'antagonistes nmda/nr2b du benzimidazole
WO2002055496A1 (fr) 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
CA2473236A1 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: 2-(4-benzyl-piperazine-1-ylmethyl)- substitue et analogues de 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1889618A4 (fr) 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Médicament combiné pour le traitement du diabète
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
JP2009533449A (ja) 2006-04-14 2009-09-17 メルク エンド カムパニー インコーポレーテッド コレシストキニン−１受容体モジュレーターとしての置換イミダゾール４−カルボキサミド類
WO2008012623A1 (fr) 2006-07-25 2008-01-31 Pfizer Products Inc. Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
BRPI0918809A2 (pt) 2008-09-11 2015-12-01 Hoffmann La Roche compostos derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são afetadas por moduladores de fxr e uso dos compostos
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
CN102946882B (zh) 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2011097491A1 (fr) * 2010-02-04 2011-08-11 Glaxosmithkline Llc Agents antiviraux à base de benzimidazole
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012088438A1 (fr) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utilisables en vue du traitement de maladies
EP2802571A1 (fr) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Dérivés de benzimidazole comme antagonistes du récepteur mch
WO2014127350A1 (fr) 2013-02-18 2014-08-21 The Scripps Research Institute Modulateurs des récepteurs de la vasopressine à pouvoir thérapeutique
WO2016029146A1 (fr) 2014-08-22 2016-02-25 University Of Washington Inhibiteurs spécifiques de la méthionyl-tarn synthétase
AU2015367977B9 (en) 2014-12-24 2020-02-06 Lg Chem, Ltd Biaryl derivative as GPR120 agonist
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
WO2017066705A1 (fr) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Composés, compositions et méthodes d'utilisation contre des granules de stress
EP3365334B1 (fr) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
EP3555064B9 (fr) * 2016-12-16 2023-03-01 Pfizer Inc. Agonistes du récepteur glp-1 et leurs utilisations
CA3045644C (fr) 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
WO2020234726A1 (fr) * 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
WO2022199661A1 (fr) 2021-03-24 2022-09-29 Eccogene (Shanghai) Co., Ltd. Dérivés d'acide phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-phényl-, phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-hétéroaryl-, ou phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-pipéridinyl-méthyl-oxétanylméthyl-1h-benzo [d] imidazole-carboxylique et leurs procédés d'utilisation
WO2022216094A1 (fr) 2021-04-08 2022-10-13 주식회사 엘지화학 Agoniste du récepteur glp-1, composition pharmaceutique le comprenant et son procédé de préparation

Also Published As

Publication number Publication date
US20240059679A1 (en) 2024-02-22
GEP20227453B (en) 2023-01-10
DK3806955T3 (da) 2023-06-26
CU20200099A7 (es) 2021-08-06
DK4219487T3 (da) 2025-02-03
TWI707683B (zh) 2020-10-21
PY1946939A (es) 2020-12-03
JP6916968B1 (ja) 2021-08-11
IL279300A (en) 2021-01-31
RS64323B1 (sr) 2023-08-31
TW202015679A (zh) 2020-05-01
EP3806955A1 (fr) 2021-04-21
EP3806955B1 (fr) 2023-05-31
US12378230B2 (en) 2025-08-05
NI202000091A (es) 2021-03-23
UY38261A (es) 2020-01-31
CN119462622A (zh) 2025-02-18
EP4219487B9 (fr) 2025-03-26
RS64323B9 (en) 2023-11-30
KR20210019529A (ko) 2021-02-22
RS66418B9 (sr) 2025-05-30
MD3806955T3 (ro) 2024-01-31
US10683281B2 (en) 2020-06-16
MX389121B (es) 2025-03-20
SI4219487T1 (sl) 2025-07-31
HUE063074T2 (hu) 2023-12-28
PL3806955T3 (pl) 2023-09-04
RS66418B1 (sr) 2025-02-28
MY199157A (en) 2023-10-18
RU2769715C1 (ru) 2022-04-05
WO2019239319A1 (fr) 2019-12-19
MX2020013625A (es) 2022-01-04
ES2949954T9 (es) 2023-11-23
PE20240584A1 (es) 2024-03-21
PT3806955T (pt) 2023-07-20
EP4219487B1 (fr) 2024-12-18
IL279300B2 (en) 2023-11-01
HUE070423T2 (hu) 2025-06-28
US20250340544A1 (en) 2025-11-06
CN112533674A (zh) 2021-03-19
CA3045644A1 (fr) 2019-12-13
US20190382384A1 (en) 2019-12-19
SG11202011465QA (en) 2020-12-30
PL4219487T3 (pl) 2025-03-31
BR112020024470A2 (pt) 2021-03-02
LT4219487T (lt) 2025-01-27
CO2020015305A2 (es) 2021-03-08
MD3806955T2 (ro) 2023-09-30
ES2949954T3 (es) 2023-10-04
PH12020552069A1 (en) 2021-05-31
NZ770240A (en) 2023-07-28
UA124371C2 (uk) 2021-09-01
US10676465B2 (en) 2020-06-09
US20190382388A1 (en) 2019-12-19
CY1126097T1 (el) 2023-11-15
AU2019285491B2 (en) 2021-11-11
GEP20237453B (en) 2023-01-10
KR102542199B1 (ko) 2023-06-13
US20210163455A1 (en) 2021-06-03
US10934279B2 (en) 2021-03-02
HRP20230631T1 (hr) 2023-09-29
US20190382387A1 (en) 2019-12-19
CN119462621A (zh) 2025-02-18
MD4219487T2 (ro) 2025-04-30
EP4219487A1 (fr) 2023-08-02
MA64510B1 (fr) 2025-03-28
DK4219487T5 (da) 2025-05-19
PT4219487T (pt) 2025-02-18
ECSP20078651A (es) 2021-01-29
GEAP202215517A (en) 2022-09-12
CN119431342A (zh) 2025-02-14
IL279300B1 (en) 2023-07-01
EP3806955B9 (fr) 2023-08-23
FI3806955T3 (fi) 2023-07-27
ZA202007572B (en) 2023-10-25
CN112533674B (zh) 2024-11-15
LT3806955T (lt) 2023-07-10
CR20200612A (es) 2021-01-20
ES3012643T3 (en) 2025-04-09
HRP20250099T1 (hr) 2025-03-28
SI3806955T1 (sl) 2023-08-31
JP2021521265A (ja) 2021-08-26
MD4219487T3 (ro) 2025-05-31
FI4219487T3 (fi) 2025-02-24
AU2019285491A1 (en) 2020-12-17
PE20211601A1 (es) 2021-08-18
CL2020003222A1 (es) 2021-04-30

Similar Documents

Publication Publication Date Title
CA3045644C (fr) Antagonistes du recepteur glp-1 et leurs utilisations
CA3163979A1 (fr) Formes solides de 2-((4-((s)-2-(5-chloropyridine-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidine-1-yle)methyle)-1-(((s)-oxetan-2-yl)methyle) -1h-benzo[d] imidazole-6-acide carb oxylique, 1,3-dihydroxy-2-(hydroxymethyle)propane-2-sel d'amine
AU2019285570A1 (en) GLP-1 receptor agonists and uses thereof
RU2769715C9 (ru) Агонисты рецептора glp-1 и их применение
EA040816B1 (ru) Агонисты рецептора glp-1 и их применение
OA19888A (en) GLP-1 receptor agonists and uses thereof.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220602

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509